{"id":"NCT01493960","sponsor":"InDex Pharmaceuticals","briefTitle":"The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients","officialTitle":"A Placebo-controlled, Double-blind, Randomised Study to Assess the Efficacy and Safety of Cobitolimod as an add-on to Current Practice in Chronic Active Treatment Refractory Ulcerative Colitis Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2013-06","completion":"2014-03","firstPosted":"2011-12-16","resultsPosted":"2018-01-24","lastUpdate":"2023-01-10"},"enrollment":131,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Colitis, Ulcerative"],"interventions":[{"type":"DRUG","name":"Cobitolimod","otherNames":["DIMS0150, Kappaproct"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cobitolimod","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if cobitolimod (former called Kappaproct®) is effective in the treatment of chronic active ulcerative colitis patients not responding to available therapy.","primaryOutcome":{"measure":"Induction of Clinical Remission","timeFrame":"Week 12","effectByArm":[{"arm":"Cobitolimod","deltaMin":44.4,"sd":null},{"arm":"Placebo","deltaMin":46.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":37,"countries":["Czechia","France","Germany","Hungary","Italy","Poland","United Kingdom"]},"refs":{"pmids":["30120066"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":87},"commonTop":["Headache","Nasopharyngitis","Anemia","Rash","Cushingoid"]}}